Thorne HealthTech Announces Two-Year Collaboration with AstraZeneca on Disease Discovery System to Advance Novel Drug Discovery

Rhea-AI Summary

Thorne HealthTech (NASDAQ: THRN) has announced a two-year extension of its collaboration with AstraZeneca to enhance drug discovery through Thorne's AI disease discovery platform. This system integrates biological and chemical data to identify new product development opportunities in nutrition and pharmaceuticals. CEO Paul Jacobson emphasized the partnership's potential to better understand complex disease mechanisms. AstraZeneca's Mike Snowden noted that this data-driven approach could accelerate the delivery of life-saving treatments.

Positive

• Two-year collaboration extension with AstraZeneca enhances drug discovery potential.
• Use of innovative AI and multi-omic platform may lead to novel drug targets.
• Validated system supported by peer-reviewed clinical research.

Negative

• None.

NEW YORK, Aug. 4, 2022 /PRNewswire/ -- Thorne HealthTech, Inc. ("Thorne HealthTech" or "Thorne") (NASDAQ: THRN), a leader in developing innovative solutions for a personalized approach to health and wellness, today announced a two-year continuation of the collaboration with AstraZeneca, a leading biopharmaceuticals company. The extended collaboration will see the internalization of Thorne's disease discovery platform into AZ for further evaluation and to gain insight into additional uses for AZ molecules.

Thorne's cloud-based AI disease discovery system integrates biology and chemistry evidence to create compound innovations for new product development in both nutrition and pharmaceutical fields. The system, which leverages a proprietary multi-omic platform and Thorne's AI models, has been validated by multiple external clinical research in peer-reviewed publications. 

"Our collaboration with AstraZeneca brings together traditional biology with innovative AI-driven technologies, representing the future of drug discovery," said Chairman and CEO of Thorne HealthTech, Paul Jacobson. "Together, we will have an improved understanding of the underlying disease mechanisms to further identify novel and biologically plausible drug targets which we know are incredibly complex."

"Embedding cutting-edge data science and AI within our research and development strategies is helping transform our ability to uncover novel drivers of disease," said Senior Vice President, Discovery Sciences, AstraZeneca, Mike Snowden. "This data-driven approach to drug discovery has the potential to expand our knowledge of disease biology and allow us to bring life-saving medicines to patients faster than ever before."

About Thorne HealthTech
Thorne HealthTech is a leader in developing innovative solutions for delivering personalized approaches to health and wellness. As a science-driven wellness company that empowers individuals with the support, education, and solutions they need to achieve healthy aging – living healthier longer – Thorne utilizes testing and data to create improved product efficacy and to deliver personalized solutions to consumers, health professionals, and corporations. Predicated on the power of the individual, Thorne leverages artificial intelligence models to provide insights and personalized data, products, and services that help individuals take a proactive and actionable approach to improve and maintain their health over a lifetime. Thorne is the only supplement manufacturer that collaborates with Mayo Clinic on health and wellness research and content, and is trusted by more than four million customers, 45,000+ health-care professionals, thousands of professional athletes, and more than 100 professional sports teams and U.S. National Teams. For more information, visit Thorne.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/thorne-healthtech-announces-two-year-collaboration-with-astrazeneca-on-disease-discovery-system-to-advance-novel-drug-discovery-301599853.html

SOURCE Thorne HealthTech, Inc.

FAQ

What is the recent announcement from Thorne HealthTech regarding AstraZeneca?

Thorne HealthTech announced a two-year continuation of its collaboration with AstraZeneca to utilize its AI disease discovery platform for drug development.

How will the collaboration with AstraZeneca benefit Thorne HealthTech investors?

The collaboration aims to enhance drug discovery, potentially leading to new revenue streams and improved market positioning for Thorne HealthTech.

What role does AI play in Thorne HealthTech's collaboration with AstraZeneca?

AI is utilized in Thorne's disease discovery platform to integrate biological and chemical data for identifying new drug targets.

What is the significance of the collaboration extension for Thorne HealthTech (THRN)?

The extension marks an ongoing commitment to innovate in drug discovery, which could positively impact Thorne HealthTech's stock performance.

When was the collaboration between Thorne HealthTech and AstraZeneca announced?

The collaboration was announced on August 4, 2022.